Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Trevi Therapeutics reports transformative year with strong financial position

Trevi Therapeutics' strong performance in 2022, backed by positive trial results and financial stability, sets the stage for continued growth.
While facing challenges such as potential delays and increased expenses, Trevi's strategic planning and diverse opportunities position the company for success.
By leveraging its strengths in clinical development and upcoming data releases, Trevi aims to build scientific evidence and attract potential partners.
Overall, Trevi's focus on advancing its pipeline and showcasing trial results highlights its commitment to addressing unmet medical needs.

Trevi Therapeutics advances Haduvio trials, navigates regulatory challenges for growth

Trevi Therapeutics showcased progress in Haduvio's clinical development and financial stability despite a net loss.
The company faces challenges in dosing strategies, patent coverage, and regulatory hurdles but is poised for growth through strategic initiatives.

Trevi Therapeutics advances Haduvio in chronic cough, overcomes financial hurdles

Trevi Therapeutics is progressing with Haduvio's development in chronic cough indications
Financially, the company is managing its resources prudently and eliminating debt
Challenges persist with study delays due to supply shortages, but opportunities for growth are evident

Trevi Therapeutics advances Haduvio trials amidst financial stability

Trevi Therapeutics' financials show resilience with a focus on clinical advancements.
Challenges in trial planning and FDA outcomes require strategic navigation.
Opportunities for growth lie in upcoming trials and conference participation.
Overall, Trevi Therapeutics is positioned for continued progress and innovation.

Trevi Therapeutics advances novel cough treatments amidst financial challenges

Trevi Therapeutics is advancing innovative treatments for refractory chronic cough. Despite financial challenges, the company's strong cash position and ongoing clinical trials position it well for future growth.

Trevi Therapeutics reports Q1 loss, progresses in clinical trials

Trevi Therapeutics faces challenges with timelines for top line data in ongoing trials but holds promise in clinical development.
The company's financial performance reflects increased R&D expenses but maintains a strong cash position for future growth.

Trevi Therapeutics reports Q2 loss, advances in key trials

Trevi Therapeutics' Q2 2024 performance reflects ongoing investment in research with a net loss of $12.4 million and R&D expenses at $10 million.
Management's strategic focus on IPF and RCC trials, along with new leadership appointments and study initiations, underpin the company's commitment to therapeutic advancements.
While facing challenges like enrollment imbalances and financial pressures, Trevi Therapeutics remains poised for growth with upcoming data readouts and a strong research pipeline.

Trevi Therapeutics reports Q3 loss, eyes upcoming milestones and trials

Trevi Therapeutics is navigating increased R&D expenses, with a strong cash position and clear focus on upcoming data milestones. Analyst inquiries and ongoing trials present challenges, while opportunities lie in defining patient populations and regulatory decisions post-NDA submission.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corporate presentation will be held on Wednesday, December 4, 2024, at 1:00 p.m. ET NEW HAVEN, Conn.

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn.

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Conference call and webcast to be held at 4:30 p.m. ET   NEW HAVEN, Conn.

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn. , Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025.

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

NEW HAVEN, Conn. , Oct. 15, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November.

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) study dosing complete; topline results expected in December 2024 NEW HAVEN, Conn. , Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today provided updates on its clinical development programs.

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V.

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.

Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER NEW HAVEN, Conn. , Sept. 26, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at CHEST 2024 held in Boston, Massachusetts from October 6-9.

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics NASDAQ: TRVI, which don't yet have any products approved by the Food and Drug Administration (FDA).

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock

Professor Jacky Smith will present on the correlation between the change in objective cough count and improvement in patient-reported outcomes with nalbuphine ER in IPF patients NEW HAVEN, Conn. , Sept. 4, 2024  /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at the European Respiratory Society (ERS) Congress 2024 being held in Vienna, Austria from September 7-11.

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

NEW HAVEN, Conn. , Aug. 28, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in September.

Trevi Therapeutics to Participate in September Investor and Medical Conferences

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Thomas Smith - Leerink Partners Leland Gershell - Oppenheimer Mayank Mamtani - B. Riley Securities Brandon Folkes - Rodman & Renshaw John Gionco - Needham & Company Debanjana Chatterjee - JonesTrading Operator Good afternoon.

Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript

Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024 in the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) Ended the second quarter of 2024 with $69.5 million in cash, cash equivalents and marketable securities with expected cash runway into 2026 Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn.

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024

Two abstracts accepted for oral presentation at the 13th London International Cough Symposium NEW HAVEN, Conn. , July 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor and medical conferences in July and August.

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Leland Gershell - Oppenheimer Jack Padovano - Stifel Nathanael Charoensook - Leerink Partners Mayank Mamtani - B. Riley Securities Operator Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2024 Earnings Conference Call.

Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript

NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor, business development and medical conferences in May and June.

Trevi Therapeutics to Participate in Upcoming Conferences

Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of 2024 Topline results continue to be expected in the first half of 2025 for the Phase 2b CORAL trial in chronic cough in IPF IND cleared with the FDA for planned Phase 1b trial to evaluate respiratory physiology in IPF patients with varying disease severity Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn.

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial NEW HAVEN, Conn. , April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22.

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick

NEW HAVEN, Conn. , April 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will attend and participate in the following events in April.

Trevi Therapeutics to Participate in Upcoming April Events

Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn. , April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development.

News for Trevi Therapeutics Inc Stock (TRVI)